Glycotest Licenses Novel Biomarker Intellectual Property from the Medical University of South Carolina to Advance Next-Generation Liver Fibrosis Staging Test

Glycotest, Inc. announced today that it has executed a license agreement with the Zucker Institute for Innovation Commercialization (ZI), the commercialization entity advancing technologies originated from the Medical University of South Carolina (MUSC), for intellectual property relating to Glycotest’s blood test for staging liver fibrosis. The licensed IP supports the expansion of Glycotest’s proprietary LRAGG biomarker into multi-biomarker panels with the potential for greater clinical performance and extended patent protection.

Under the terms of the agreement, Glycotest receives exclusive worldwide rights to the licensed intellectual property, and ZI will receive a royalty on future product sales, along with other financial consideration.

Accurate staging of liver fibrosis is essential to managing patients with chronic liver disease, helping guide treatment decisions and monitor disease progression. The need for accessible, effective fibrosis assessment is particularly acute in the rapidly growing population with metabolic dysfunction-associated steatotic liver disease (MASLD) and MASH, where identifying clinically meaningful fibrosis before progression to advanced disease can inform patient management. MASLD affects an estimated 100 million U.S. adults and more than 1 billion people worldwide, creating a substantial and growing need for noninvasive fibrosis assessment. Clinical guidelines recommend periodic fibrosis assessment for at-risk patients, representing a global market opportunity projected* to reach as high as $3B by 2033. Through its clinical laboratory services business model, Glycotest is committed to providing physicians and patients with convenient, objective, blood-based tools for liver fibrosis staging.

Charles Swindell, PhD, CEO, Glycotest, commented:

“This license agreement with ZI is an important step in strengthening our liver fibrosis staging pipeline. By expanding our proprietary LRAGG biomarker into a multi-biomarker panel, we believe we can deliver even greater clinical performance while extending the intellectual property protection around our technology. We are excited to work with Professor Mehta and his team, whose deep expertise in glycoproteomic biomarker discovery is highly complementary to our mission of bringing novel non-invasive tests to patients with liver disease.”

The newly licensed intellectual property was developed by Professor Anand Mehta, DPhil, who holds the SmartState Chair in Proteomic Biomarkers at MUSC and is a recognized leader in the discovery and validation of glycoprotein and proteomic biomarkers for liver disease.

Anand Mehta, DPhil, SmartState Chair in Proteomic Biomarkers, MUSC, said:

“Our research has focused on identifying biomarkers that can meaningfully improve the accuracy of non-invasive liver fibrosis staging, particularly for patients in the intermediate stages of disease who stand to benefit most from early intervention. Licensing this intellectual property to Glycotest gives it a clear path toward the clinic, and I look forward to collaborating with their team to advance a next-generation, multi-biomarker panel that builds on the LRAGG platform.”

Liver fibrosis affects millions of patients worldwide, with rising prevalence driven in large part by the growing burden of MASH. Non-invasive, blood-based staging tools are increasingly viewed as essential to identifying patients who require closer monitoring or intervention before disease progresses to cirrhosis, the point at which treatment options narrow considerably.

About Glycotest, Inc.

Glycotest is a private liver disease diagnostics company with a pipeline of clinical-stage blood tests for hepatocellular carcinoma, cholangiocarcinoma and fibrosis.  The Company is focused on the estimated $4B global liver cancer surveillance and fibrosis staging market. Glycotest was spun out of the Philadelphia area institutions Baruch S. Blumberg Institute and Drexel University College of Medicine and is backed by the London-based VC investor EMV Capital and other private investors. Learn more at https://www.glycotest.com

About the Medical University of South Carolina

The Zucker Institute for Innovation Commercialization is the commercialization organization for the Medical University of South Carolina (MUSC), working to translate MUSC discoveries into products, services and companies that improve health and generate economic impact. The Zucker Institute manages MUSC intellectual property and works with faculty, entrepreneurs, investors and industry partners to advance promising innovations toward the marketplace. Learn more at https://www.zuckerinnovation.org/

Media Contact

Glycotest, Inc.

Charles@glycotest.com

*Grand View Research, Hepatic Fibrosis Biomarkers Market Analysis Report (2025–2033); Coherent Market Insights, Transient Elastography Devices Market Forecast

Leave a Comment